comparemela.com
Home
Live Updates
IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4 : comparemela.com
IMAB On Watch, GTH Expects 2022 Revenue To Grow 10-20%, PHVS To Report HAE Trial Data In Q4
(RTTNews) - The following are some of the companies belonging to the healthcare sector that reported fourth quarter results and provided an update...
Related Keywords
China
,
United States
,
American
,
,
Adverum Biotechnologies Inc
,
Somalogic Inc
,
Genetron Holdings Ltd
,
Biosciences Inc
,
Monte Rosa Therapeutics Inc
,
Humacyte Inc
,
American Association For Cancer Research Annual Meeting
,
Akouos Inc
,
Biocardia Inc
,
Candel Therapeutics Inc
,
Cue Health
,
Rani Therapeutics Holdings Inc
,
Infinity Pharmaceuticals Inc
,
Genetron Health
,
Therapy Heart Failure Trial
,
Therapy Chronic Myocardial Ischemia
,
Data Safety Monitoring Board
,
Myocardial Ischemia
,
Positive Mesenchymal Stem Cells
,
Nasdaq Global Select Market
,
New Drug Applications
,
Biologics License Application
,
Acute Myeloid
,
Rosa Therapeutics
,
Investigational New Drug
,
American Association
,
Cancer Research Annual Meeting
,
Therapeutics Holdings
,
comparemela.com © 2020. All Rights Reserved.